28 October 2015 -  CADTH's CDEC has recommended that vedolizumab be listed for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, loss of response to, or were intolerant to either conventional therapy or infliximab, if certain clinical criterion and condition are met.

For more details, go to: https://www.cadth.ca/sites/default/files/cdr/complete/SR0421_cdr_complete_Entyvio_Nov-2-15_e.pdf